Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial

Published:2022-12 Issue:12 Volume:10 Page:869-881
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Inzucchi Silvio E,Claggett Brian L,Vaduganathan Muthiah,Desai Akshay S,Jhund Pardeep S,de Boer Rudolf A,Hernandez Adrian F,Kosiborod Mikhail N,Lam Carolyn S P,Martinez Felipe,Shah Sanjiv J,Verma Subodh,Han Yaling,Kerr Saraiva Jose F,Bengtsson Olof,Petersson Magnus,Langkilde Anna Maria,McMurray John J V,Solomon Scott D

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference31 articles.

1. Heart failure in type 2 diabetes mellitus;Kenny;Circ Res,2019

2. The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure

3. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis;Castagno;Am Heart J,2011

4. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis;McGuire;JAMA Cardiol,2021

5. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med,2019

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin Use in Children with Advanced Heart Failure Undergoing Heart Transplantation: A Matched Case-Control Study;Pediatric Cardiology;2024-07-22

2. Update on evidence-based clinical application of sodium-glucose cotransporter inhibitors: Insight to uncommon cardiovascular disease scenarios in diabetes;World Journal of Diabetes;2024-07-15

3. Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial;Cardiovascular Diabetology;2024-07-11

4. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis;The Lancet Diabetes & Endocrinology;2024-07

5. The Interplay of Comorbidities in Chronic Heart Failure: Challenges and Solutions;Current Cardiology Reviews;2024-05